Physician profile
Ashokkumar J Kothari
NPI 1265431332
$2,379.46
in general payments reported to CMS, 2019-2025
28 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2021: $33.45 · 2022: $664 · 2023: $454 · 2024: $462 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $300.62 | 2019-2022 | |
| Grifols USA, LLC | $250.12 | 2022-2024 | Prolastin-C Liquid, Xembify |
| Novartis Pharmaceuticals Corporation | $242.27 | 2019-2025 | |
| Medtronic, INC. | $189.25 | 2022-2025 | Cobalt Dr Mri Surescan, Amplia Mri Quad Crt-D Surescan |
| Mallinckrodt Hospital Products INC. | $164.36 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $157.13 | 2023-2025 | Dupixent |
| Amgen INC. | $110.78 | 2019-2024 | Repatha, Tezspire |
| Boston Scientific Corporation | $104.76 | 2024-2025 | Watchman, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.82 | 2021-2023 | Spiriva Respimat |
| Edwards Lifesciences Corporation | $97.35 | 2023 | Sapien 3 Ultra Resilia |
| Electromed, INC. | $89.02 | 2022-2023 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $82.53 | 2024-2025 | |
| Novo Nordisk INC | $73.28 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $58.01 | 2022-2023 | Camzyos |
| Merck Sharp & Dohme LLC | $56.96 | 2022-2023 | Verquvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $54.48 | 2023-2025 | Optimizer, Optimizer |
| Pfizer INC. | $28.52 | 2025 | |
| Vapotherm INC | $25.96 | 2022 | |
| Scpharmaceuticals INC. | $25.96 | 2024 | |
| United Therapeutics Corporation | $23.97 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.27 | 2025 | Onpattro |
| Vifor Pharma, INC. | $22.04 | 2025 | Veltassa |
| Mylan Specialty L.P. | $19.27 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $19.10 | 2024 | Farxiga |
| Philips North America LLC | $17.64 | 2023 | |
| Glaxosmithkline, LLC. | $16.89 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.73 | 2021 | |
| Inogen, INC. | $10.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashokkumar Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.